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export lipids from the liver to peripheral tissues and are the disease (NAFLD); 11 with hypertriglyceridemia and 22 with
precursors of low-density-lipoproteins. Low levels of hepatic
S-adenosylmethionine (SAMe) decrease triglyceride (TG)
secretion in VLDLs, contributing to hepatosteatosis in methionine
adenosyltransferase 1A knockout mice but nothing is known
about the effect of SAMe on the circulating VLDL metabolism.
We wanted to investigate whether excess SAMe could disrupt
VLDL plasma metabolism and unravel the mechanisms involved.
Methods: Glycine N-methyltransferase (GNMT) knockout (KO)
mice, GNMT and perilipin-2 (PLIN2) double KO (GNMT-PLIN2-
KO) and their respective wild type (WT) controls were used. A
high fat diet (HFD) or a methionine deﬁcient diet (MDD) was
administrated to exacerbate or recover VLDL metabolism,Journal of Hepatology 20
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Results:We found that excess SAMe increases the turnover of
hepatic TG stores for secretion in VLDL in GNMT-KO mice, a
model of NAFLD with high SAMe levels. The disrupted VLDL
assembly resulted in the secretion of enlarged, phosphatidyleth-
anolamine-poor, TG- and apoE-enriched VLDL-particles; special
features that lead to increased VLDL clearance and decreased
serum TG levels. Re-establishing normal SAMe levels restored
VLDL secretion, features and metabolism. In NAFLD patients,
serum TG levels were lower when hepatic GNMT-protein expres-
sion was decreased.
Conclusions: Excess hepatic SAMe levels disrupt VLDL assembly
and features and increase circulating VLDL clearance, which will
cause increased VLDL-lipid supply to tissues and might contrib-
ute to the extrahepatic complications of NAFLD.
 2014 European Association for the Study of the Liver. Published
by Elsevier B.V. Open access under CC BY-NC-ND license.Introduction
The liver plays a central role in whole body metabolic homeosta-
sis. It can obtain lipids from the circulation, synthesize them and
secrete them in lipoproteins into the blood stream. Very-
low-density lipoproteins (VLDL) transport triglycerides (TG) from
the liver to peripheral tissues, providing an energy source. Plasma
levels of VLDL are deﬁned by the rate of clearance from plasma
and the rate of hepatic secretion, so an imbalance between these
two processes will lead to dyslipidemia, highly associated with
increased risk of cardiovascular disease [1,2], which is one of
the extrahepatic complications of non-alcoholic fatty-liver dis-
ease (NAFLD) [3].15 vol. 62 j 673–681
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Individuals with NAFLD exhibit disrupted VLDL metabolism
[4,5]. In fact, abnormalities in the hepatic uptake of lipoproteins
and/or secretion of VLDL can lead to hepatosteatosis [6,7].
The hepatic VLDL secretion rate is regulated by a variety of
factors that must guarantee release of adequate amounts of TGs
from the liver. To ensure VLDL secretion, apolipoprotein (apo) B
should be translocated in the lumen of the endoplasmic reticu-
lum (ER) during its translation [8], where it interacts with the
microsomal TG transfer protein (MTP), whose lipid transfer activ-
ity is one of the major determinants in VLDL secretion [9]. ApoE
facilitates ApoB maturation and VLDL assembly and secretion
[10,11], and it mediates cellular uptake of several lipoproteins
from the circulation [12,13].
Most of VLDL-TG (60–70%) is derived from intracellular stores
[14,15]; therefore, the mobilization of lipids from cytosolic lipid
droplets towards the ER represents a potentially regulated step
in VLDL production and secretion [15,16].
Low liver S-adenosylmethionine (SAMe) in methionine adeno-
syltransferase 1A (MAT1A)-KO mice decreases TG secretion into
VLDL particles, which contributes to hepatosteatosis [6]. Glycine
N-methyltransferase (GNMT) drives the catabolism of SAMe and
its deﬁciency in mice results in a marked increase in hepatic
SAMe content and rapid NAFLD development [17]. SAMe is the
methyl donor required for the methylation of phosphatidyletha-
nolamine (PE). In hepatocytes, around 30% of phosphatidylcho-
line (PC) is synthesized by the sequential methylation of PE, in
a reaction catalysed by the enzyme PE N-methyltransferase
(PEMT) [18]. We have found that the ﬂux from PE to PC and its
catabolism into diglycerides (DGs) and conversion into TGs is
stimulated in the liver of GNMT-KO mice [19]. There is a require-
ment for PEMT in the liver to ensure normal VLDL secretion
[18,20]. Thus, we have evaluated if high levels of hepatic SAMe
will disrupt VLDL assembly and as a consequence VLDL features
and plasma metabolism.Materials and methods
Human samples
This study comprised 33 non-diabetic patients with cholelithiasis and a clinical
diagnosis of NAFLD without necroinﬂammation or ﬁbrosis (Supplementary Tables
1 and 2) and 36 patients with asymptomatic cholelithiasis in whom a liver biopsy
was taken during programmed laparoscopic cholecystectomy (Supplementary
Table 1). Inclusion criteria for patients are detailed in the Supplementary data
section. The study was performed in agreement with the Declaration of Helsinki
and with local and national laws. The Human Ethics Committee of the University
Hospital Santa Cristina and the University of Basque Country approved the study
procedures and written informed consent was obtained from all patients before
inclusion in the study.Animals
3-month-old male GNMT-KO mice, GNMT-PLIN2-KO mice, PLIN2-KO mice and
their WT littermates were produced in the animal facility of CIC bioGUNE. They
were maintained on different diets detailed in supplemental information. Animal
procedures were approved by the University of the Basque Country and CIC
bioGUNE Animal Care and Use Committees.
Preparation of labelled VLDL particles and in vivo clearance
Labelled human VLDL particles were obtained by a method previously described
[21,22] and as detailed in the Supplementary Materials and methods.674 Journal of Hepatology 201Quantiﬁcation of lipids
Lipids were extracted and quantiﬁed as described before [23]. TGs were quanti-
ﬁed using a commercially available kit (A. Menarini Diagnostics). PE, PC, and
DG were separated by thin layer chromatography and quantiﬁed as detailed else-
where [24].
Statistical analysis
Data were represented as means ± SEM. Differences between groups were tested
using the Student’s t test and two way ANOVA. Signiﬁcance was deﬁned as
p <0.05. The baseline characteristics of the patients studied were compared using
the unpaired t test or Mann-Whitney U test. These analyses were performed using
SPSS version 15.0 software and GraphPad Version 5.03.
Additional methods are detailed in the Supplementary Materials and meth-
ods section.Results
Deletion of GNMT disrupts VLDL assembly, VLDL features and decreases
circulating VLDL levels in serum
GNMT-KO mice show steatosis and ﬁbrosis with increased serum
aminotransferases [17] and no signs of insulin resistance [19]. In
GNMT-KO mice VLDL-TG secretion was increased whereas VLDL-
PE was decreased as compared to their wild-type (WT) controls
(Fig. 1A). No changes were observed with regard to VLDL-PC
secretion (Fig. 1A), while the VLDL size was augmented in
GNMT-KO mice (Fig. 1A). All these compositional and physical
VLDL features restored after feeding a methionine deﬁcient diet
(MDD) for 3 weeks (Fig. 1A). Consistent with the increased
VLDL-TG secretion, we found increased turnover of the hepato-
cyte TG lipid stores (Fig. 1B) and increased MTP and diacylglyc-
erol O-acyltransferase (DGAT) activity while no changes in TG
lipase activity (Supplementary Fig. 1A) were observed. The
increased hepatocyte TG secretion was re-established after inhi-
bition of PEMT with 3-deazaadenosine (DZA) (Fig. 1C).
One of the factors that deﬁne the levels of circulating TGs in
blood is the hepatic secretion rate. To our surprise, GNMT deletion
in mice resulted in a decrease of serum TG (Fig. 1D), due to most
of all VLDL and some LDL subfractions (Fig. 1D). The decrease in
VLDL and LDL was also evident when ApoB levels were analysed
in serum (Supplementary Fig. 1B). Re-establishing SAMe hepatic
levels, by feeding MDD, restored serum TG and ApoB levels in
GNMT-KO mice (Fig. 1D and Supplementary Fig. 1B).
In patients with NAFLD (n = 33) serum TG levels ranged from
54 to 317 mg/dl showing a high heterogeneity among subjects
(Supplementary Table 1). In order to investigate whether altered
SAMe metabolism could be linked with increased VLDL clearance
in patients with NAFLD, we classiﬁed the individuals into two
groups depending on serum TG levels (Supplementary Table 2).
In a ﬁrst group, (NAFLD-1), we introduced those subjects with
serum TG levels higher than the mean of TGs in NAFLD patients
(130.1 mg/dl) (n = 11) and in a second group (NAFLD-2) we
included those with TG levels below 130.1 mg/dl (n = 22). We
quantiﬁed TG levels in serum and analysed TG distribution in
lipoproteins in the serum of the two groups (Fig. 1E) and found
that decreased TG levels corresponded to most of all VLDL and
some LDL subfractions (Fig. 1E). We also found that in NAFLD-2
patients there is a shift to the left of the maximum peak of VLDL,
indicating that VLDL particles are enlarged (Fig. 1E). High hepatic
SAMe levels in GNMT-KO mice were linked with enlarged VLDL5 vol. 62 j 673–681
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Fig. 1. Deletion of GNMT disrupts VLDL features and serum VLDL clearance.Wild type (WT),GNMT-KO (KO) andGNMT-KOmice fed aMDD (KOMDD)were fasted for 2 h.
(A) Before the injection of 1 g/kg poloxamer (P-407) and 6 h later, VLDLs were isolated from the serum and characterized for triglyceride (TG), phosphatidylethanolamine (PE)
and phosphatidylcholine (PC) content and VLDL size. (B) Hepatocytes were incubated with 0.4 mM [3H] oleic acid (5 lCi/dish) and [14C] glycerol (0.5 lCi/dish) (pulse). The
percentage of total [3H]-TG and [14C]-TG secreted into the media after both the pulse (4 h) and chase periods (4 h) was calculated. (C) Hepatocytes were incubated with 3-
deazaadenosine (DZA, 10 lM) for 4 h and TG secretion into the mediumwas determined. (D) TG levels in serum and in lipoprotein subfractions were measured in mice fed a
control diet. (E) Serum samples from NAFLD patients were obtained after a 12 h overnight fast. Serum samples from NAFLD-1 and NAFLD-2 patients were pooled and the TG
content in serum lipoprotein subfractions was quantiﬁed. (F) Liver samples from patients with NAFLD (n = 17) (6 fromNAFLD-1 and 11 fromNAFLD-2) were obtained by liver
biopsy GNMT immunohistochemistry. Magniﬁcation 40. Quantitative assessments of IHC staining were performed using FRIDA image analysis software, expressed in % of
positive staining per area. A negative control (NC) was performed by omission of primary antibody. Values are mean ± SEM of 5–6 animals per group and of the previously
indicated patients. Statistical differences between GNMT-KO andWTmice or NAFLD-1 and NAFLD-2 patients are denoted by ⁄p <0.05; ⁄⁄p <0.01; ⁄⁄⁄p <0.001 (Student’s t test);
and differences between GNMT-KO and GNMT-KO fed a MDD are denoted by #p <0.05; ##p <0.01 (Student’s t test). (This ﬁgure appears in color on the web.)
JOURNAL OF HEPATOLOGYparticles (Fig. 1A), while decreased hepatic SAMe levels have
been reported to be linked with smaller VLDL particle size [6],
so we hypothesized that the SAMe content could also be
increased in NAFLD-2 patients as a consequence of decreased
GNMT expression. It has recently been described [25,26] thatJournal of Hepatology 201expression of the GNMT andMAT1A genes is decreased in patients
with severe NAFLD. Thus, we measured GNMT protein levels
in 17 NAFLD liver samples (6 from NAFLD-1 and 11 from
NAFLD-2) and observed that in NAFLD-2 liver samples GNMT
protein levels were lower than in livers from NAFLD-1 patients5 vol. 62 j 673–681 675
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(Fig. 1F). When compared with normal livers (NL), GNMT protein
expression was not changed in livers from NAFLD-1 subjects,
while in livers from NAFLD-2 subjects the decrease was evident
(Supplementary Fig. 2A). The hepatic PE content was decreased
in NAFLD-2 patients, making the PC to PE ratio higher (Supple-
mentary Fig. 2B), which suggests increased PEMT ﬂux and
VLDL secretion. Thus, in NAFLD-2 patients decreased TG levels
in serum could be due to increased VLDL clearance as a conse-
quence of increased hepatic SAMe levels.
A high fat diet (HFD) induces VLDL clearance and TG storage in the
livers of GNMT-KO mice
We observed that excess SAMe in the liver increased VLDL-TG
secretion as a consequence of increased PEMT ﬂux, increased
MTP activity, and increased turnover of TG lipid stores. HighLiver hepatocyte
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676 Journal of Hepatology 201levels of hepatic SAMe also transformed VLDL features and
increased VLDL clearance from blood (Fig. 2). We wondered
whether challenging the mice with a HFD for six weeks could
affect differently WT and GNMT-KO mice, exacerbating VLDL
secretion and clearance in GNMT-KO mice. The metabolic charac-
terization of mice fed a HFD showed that in GNMT-KO mice the
food intake was slightly decreased as compared to their WT
counterparts (Supplementary Fig. 3A). The body weight and the
% of WAT did not change (Supplementary Fig. 3B and C), while
the % of liver weight was increased (Supplementary Fig. 3D) as
when fed a control diet (CD) [19]. GNMT-KO mice fed a HFD did
not exhibit insulin resistance (Supplementary Fig. 3E). The HFD
induced VLDL-TG secretion was observed only in GNMT-KO mice
if compared with animals that were fed the control diet (CD)
(Fig. 3A and Fig. 1A). The HFD did not alter VLDL-PE or VLDL-PC
secretion nor VLDL size since the observed changes, whenBlood stream
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Fig. 3. HFD induces VLDL clearance and liver TG storage in GNMT-KO mice.Wild typemice fed ahigh fat diet (WTHFD) andGNMT-KOmice fed aHFD (KOHFD)were fasted
for 2 h. (A) Before the 1 g/kg poloxamer (P-407) injection and 6 h later, VLDL particles were isolated from the serum and characterized for triglyceride (TG),
phosphatidylethanolamine (PE) and phosphatidylcholine (PC) content and VLDL size. (B) TG levels in serum and in lipoprotein subfractions were measured. (C) Liver
triglyceride (TG), diglyceride (DG), phosphatidylethanolamine (PE) and phosphatidylcholine (PC) levels fromWT and KOmice fed theHFDwere quantiﬁed. (D) Representative
liver haematoxylin and eosin staining. (E) Percentage of heart weight. Heart TG levels were quantiﬁed after lipid extraction. Values are mean ± SEM of 4–5 animals per group.
Statistical differences between KO and WT mice are denoted by ⁄p <0.05; ⁄⁄p <0.01; ⁄⁄⁄p <0.001 (Student’s t test). (This ﬁgure appears in color on the web.)
JOURNAL OF HEPATOLOGYcompared to their controls (Fig. 3A), were of the same magnitude
as when fed a CD (Fig. 1A). Even though the HFD increased VLDL-
TG secretion, serum TG levels were still half those in WT mice,
indicating higher VLDL clearance in GNMT-KO mice fed the HFD
compared to the CD (Fig. 3B). The low TG levels in serum were
also due to a decrease in VLDL and some LDL subfractions
(Fig. 3B).
In a condition in which VLDL clearance is increased, VLDL lipid
supply to tissues will also be increased. After feeding the HFD the
liver TG levels were 2.75 fold increased as compared to their WTs
(Fig. 3C and D), whereas when fed a CD the increase of TG in liverJournal of Hepatology 201was of a 75% [19]. The altered hepatic DG, PE and PC content in
GNMT-KO mice fed the HFD maintained as when fed the CD
[19]. When fed the HFD the TG storage in heart was twice the
WT value (Fig. 3E) whereas when fed a CD it was not increase
(data not shown).
The HFD did not modify mRNA levels of proteins involved in
lipid synthesis and NADPH production in GNMT-KO mice if com-
pared to their controls (Supplementary Fig. 3F). Serum ketone
bodies and fatty acids (Supplementary Fig. 3G) were not changed,
and the hepatic CD36 protein content was not increased (Supple-
mentary Fig. 3H).5 vol. 62 j 673–681 677
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Speciﬁc VLDL features in GNMT-KO mice are linked with increased
VLDL clearance
To deﬁne if the increased VLDL clearance depended on speciﬁc
features of GNMT-KO VLDL particles, human VLDL particles were
labelled and administered intravenously to GNMT-KO and WT
mice. We found that the kinetic of clearance of labelled human
VLDL was similar in WT and GNMT-KO mice (Fig. 4A), and that
the % of injected dose per g of tissue after 30 min of injection
was not altered in GNMT-KO mice (Fig. 4A), verifying that the
increased clearance depended only on speciﬁc features of
GNMT-KO VLDL particles.
To go further in the characterization of VLDL features from
GNMT-KO mice we analysed VLDL-ApoB and -ApoE secretion. In
GNMT-KO mice the secretion of VLDL-ApoB100 was decreased,
while no changes were observed in those VLDL particles bearing
ApoB48 as compared to their WT controls (Fig. 4B). Each VLDL
particle contains a single copy of ApoB but several copies of ApoE.
The results showed that in GNMT-KO mice, VLDL-ApoE secretion
was increased compared to WT mice (Supplementary Fig. 4A), an
increase even higher when fed the HFD (Supplementary Fig. 4A).
This made each secreted VLDL particle to be ApoE-enriched
(Fig. 4C). We observed that the altered VLDL-ApoE (Supplemen-
tary Fig. 4A) and VLDL-ApoB100 secretion (Fig. 4B) responded
to changes in the hepatic content of these proteins and restored
after re-establishing hepatic SAMe levels (Fig. 4D and E).
It has been suggested that lysosomal enzymes may degrade
part of ApoE [27], so we investigated the effect of NH4Cl/leupep-
tin inhibitors. The treatment did not induce changes in GNMT-KO
or WT hepatocytes ApoE levels (Supplementary Fig. 4B). In addi-
tion, we observed that in GNMT-KO mice there is an accumula-
tion of ubiquitinated proteins (Supplementary Fig. 4C) and
since part of ApoE is degraded through proteasomes in HepG2
cells [28], we wondered whether the increased ApoE content
could be due to decreased proteasomal degradation. Inhibition
of proteasome function using MG132 did not increase ApoE levels
in WT hepatocytes (Supplementary Fig. 4C) nor VLDL-ApoE secre-
tion (data not shown) and decreased ApoE content in GNMT-KO
mice hepatocytes (Supplementary Fig. 4C) and secretion in VLDL
(data not shown).
Increased ApoE levels in the liver were not linked with
changes in ApoE mRNA (Supplementary Fig. 4D). However, the
decreased hepatic ApoB100 content, driven by the excess hepatic
SAMe, as shown after feeding the MDD (Fig. 4E), was coupled to
lower levels of ApoB mRNA (Fig. 4F), in which binding to the
mRNA stabilizing HuR protein was reduced (Fig. 4F). Knowing
that global DNA methylation is increased in GNMT-KO mice
[17], we wondered whether the ApoB promoter could also be
more methylated than in WT mice. We analysed six CpG sites
within the liver ApoB promoter; of which three were signiﬁcantly
hypermethylated in KO compared to WT mice (Fig. 4F). After
restoring hepatic SAMe levels, ApoB mRNA levels re-established
as did binding to HuR and methylation levels in those three
CpG sites (Fig. 4F).
Factors that regulate cytosolic lipid storage, such as PLIN2 also
inﬂuence VLDL secretion [29]. We have previously shown that
HFD induces hepatic TG storage and increases VLDL-ApoE secre-
tion in GNMT-KO mice, whereas deletion of PLIN2 in GNMT-KO
mice results in the reduction of hepatic TG levels [19]. We
wanted to know whether absence of PLIN2 in GNMT-KO mice
could disturb VLDL assembly, VLDL-apoE secretion and VLDL678 Journal of Hepatology 201clearance. PLIN2 deletion in GNMT-KO mice (GNMT-PLIN2-KO)
leads to increased VLDL-TG secretion, decreased VLDL-PE secre-
tion and increased size of VLDL already observed in GNMT-KO
mice when compared to their controls (Supplementary Fig. 5A).
Surprisingly, the absence of PLIN2 in GNMT-KO mice led to an
increase in VLDL-PC secretion not found in GNMT-KO mice (Sup-
plementary Fig. 5A), supporting a described role of PLIN2 binding
PC [30,31]. In PLIN2-KO mice VLDL-TG secretion was also
increased while no other changes were found (Supplementary
Fig. 6A and B). Turnover of TG stores for secretion into VLDL
and serum TG levels were decreased in the double KO mice if
compared to their controls (Supplementary Fig. 5B and C).
VLDL-ApoE and -ApoB secretion changed in the same way as in
GNMT-KO mice, leading also to the secretion of ApoE-enriched
VLDL particles (Supplementary Fig. 5D). Thus, the storage of
TGs in lipid droplets in GNMT-KO mice does not have any effect
on VLDL-ApoE secretion. Instead, the increased ApoE availability
is directly linked with excess SAMe levels.
Discussion
VLDL assembly depends on the hepatic availability of lipids, cer-
tain proteins and multiple enzymatic reactions [32]. Speciﬁc fea-
tures of VLDL, among other factors, deﬁne the rate of VLDL
clearance from the blood stream [33]. VLDL particles export lipids
from the liver to tissues and when lipid supply is excessive, met-
abolic homeostasis in peripheral tissues may disrupt [34]. Excess
SAMe levels in GNMT-KO mice induce PC synthesis, through the
PEMT pathway [19]. The PEMT pathway is required to ensure
VLDL secretion [20], and the conversion of PE into PC seems to
be involved in the formation of lipid droplets [35], in which
mobilization of lipids represents a regulated step in VLDL secre-
tion [15,16]. The increased PEMT ﬂux in GNMT-KO mice is
responsible for the rise in VLDL-TG secretion, which is linked
with the increased mobilization of hepatic TG stores, and higher
MTP and DGAT activity. Inhibition of DGAT1 reduces liver ﬁbrosis
in mice with NASH [36] while inhibition of DGAT2 results in
decreased hepatosteatosis but higher ﬁbrosis and liver damage
[37]. In 8-month-old GNMT-KO mice, liver ﬁbrosis is more prom-
inent [17] and DGAT activity is increased to a higher degree than
in 3-month-old KO mice, while DGAT2 mRNA is decreased 40% as
compared to their WTs. No changes have been found in DGAT2 or
DGAT1mRNA in 3-month-old KO mice (data not shown). All these
suggest a role of DGAT1 and DGAT2 in the progression of NAFLD
in GNMT-KO mice.
The increased PEMT ﬂux also causes a reduction in hepatic PE
[19], reproduced in decreased VLDL-PE secretion. Surprisingly,
even though PC synthesis was increased in GNMT-KO mice no
changes were found in VLDL-PC secretion; however, deletion of
PLIN2 in GNMT-KO mice, in which PLIN2 expression is increased
[19], results in the rise of VLDL-PC secretion, suggesting a role
of PLIN2 in the retention and catabolism of PC. PLIN2 binds lipids
such as PC with high afﬁnity, which supports this hypothesis
[31]. As expected, these changes were not observed in PLIN2-
KO mice, in which PC synthesis was not increased.
High levels of SAMe in GNMT-KO mice led to the secretion of
enlarged, PE-poor and TG- and ApoE-enriched VLDL particles.
These features facilitate VLDL clearance from the blood. We have
also observed that in a group of patients with NAFLD, serum TG
levels were decreased and the VLDL size increased when hepatic
GNMT protein levels were lower. Moylan et al. (2014) [25] have5 vol. 62 j 673–681
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Fig. 4. Speciﬁc VLDL features inGNMT-KOmice are linkedwith increased VLDL clearance.Wild type (WT),GNMT-KO (KO),GNMT-KOmice fed aMDD (KOMDD), wild type
mice fed a high fat diet (WT HFD) and GNMT-KO mice fed a HFD (KO HFD) were fasted for 2 h. (A) VLDL clearance rate was measured after intravenous administration of
radiolabeled VLDL particles. The percentage of injected radiolabel dose per gram of tissue was calculated. Before the 1 g/kg poloxamer (P-407) injection and 6 h later, VLDL
particles were isolated from the serum and characterized for (B) ApoB and ApoE content. (C) The ratio of ApoE/ApoBwas calculated. Liver ApoE (D) and ApoB (E) content in the
liver from mice was assessed by immunoblotting using transferrin as loading control. (F) Quantitative RT-PCR analysis of ApoB mRNA. Binding of ApoB mRNA to HuR was
evaluated in livers by immunoprecipitation followed by quantitative real-time PCR. The % of methylation of CpG sites within the ApoB promoter was assessed by bisulﬁte
pyrosequencing. Values are mean ± SEM of 4–6 animals per group. Statistical differences between GNMT-KO and WT mice are denoted by ⁄p <0.05; ⁄⁄p <0.01; ⁄⁄⁄p <0.001
(Student’s t test) and by two-way ANOVA; differences between GNMT-KO and GNMT-KO fed a MDD are denoted by #p <0.05; ##p <0.01; ###p <0.001 (Student’s t test).
JOURNAL OF HEPATOLOGYrecently found that patients with severe NAFLD exhibit a signiﬁ-
cant downregulation ofMAT1A and GNMT gene expression. We do
not know whether MAT protein expression, involved in SAMeJournal of Hepatology 201synthesis, may be decreased in this group of NAFLD patients
but the enlarged VLDL size, decreased hepatic PE levels and
increased PC/PE ratio suggest that the balance between GNMT5 vol. 62 j 673–681 679
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and MAT activity results in increased hepatic SAMe levels, which
enhance the PEMT ﬂux. Unfortunately, the SAMe content could
not be measured in liver biopsies from patients with NAFLD used
in the present study. All this supports the hypothesis that admin-
istration of SAMe, to improve liver disease and lipoprotein
metabolism, will have beneﬁcial effects only in that group of
patients in which the hepatic SAMe content is decreased. When
the SAMe content is increased, probably a methionine deﬁcient
diet could be the chosen treatment, according to the results
obtained previously [19] and in this work.
In the absence of ApoE, VLDL catabolism from the blood is
heavily impaired [38], resulting in increased levels of TGs and a
decreased uptake of TG-rich lipoproteins as has been observed
in ApoE-deﬁcient mice [39]. Since overexpression of ApoE mark-
edly reduces ApoB-containing lipoproteins in plasma [13], we
propose that high hepatic SAMe levels lead to VLDL-ApoE enrich-
ment. This will explain the increased VLDL clearance in GNMT-KO
mice, a feature more marked in animals fed a HFD, in which clear-
ance is higher and the heart and liver TG storage is increased,
which could be taken as a consequence of excessive lipid supply
to these tissues. The fact that no changes in serum fatty acids or
ketone bodies, together with the lack of an increase in CD36 pro-
tein levels or in genes related with lipogenesis in GNMT-KO ani-
mals fed the HFD, support this proposal. CD36 is upregulated in
livers of NASH patients [40] and CD36mRNA increases in animals
fed a HFD after partial hepatectomy [41]. However, in obese fa/fa
Zucker rats, where CD36 mRNA levels are increased, the protein
content in hepatocytes did not change [42]. mTOR selectively reg-
ulates the expression of CD36 at a translational level [43,44]. We
have found that phosphorylation of S6 and 4E-BP1, which are
mTOR targets, (data not shown) are decreased in GNMT-KO mice
fed the HFD, while CD36mRNA is increased (data not shown), sug-
gesting that downregulation of the mTOR pathway in this model
could suppress, at least in part, CD36 translation.
ApoE secretion in VLDL was increased as a consequence of the
higher liver ApoE content, which is also modulated by hepatic
SAMe levels. In HepG2 ApoE is partially degraded through the
proteasome [28] and partially through lysosomal enzymes [27];
however, our results show that in hepatocytes from GNMT-KO
mice and their WT controls other mechanisms are involved in
regulating ApoE availability. Interestingly, ApoE can escape deg-
radation and can be re-secreted when following LDLR-mediated
internalization by liver cells [45]. This is an attractive hypothesis
since VLDL clearance is increased in GNMT-KO mice; therefore,
ApoE could be recycled by the cell several times until ﬁnal degra-
dation occurs, as has been suggested before [45].
Factors that regulate cytosolic lipid storage, such as PLIN2 or
CIDEB also inﬂuence VLDL secretion [29,46]. We observed that
the HFD induced hepatic TG storage and increased VLDL-ApoE
secretion in GNMT-KO mice whereas the absence of PLIN2 in
GNMT-KO mice resulted in the reduction of hepatic TG levels,
so we thought that cytosolic lipid storage could inﬂuence ApoE
secretion into VLDL particles. However, while deletion of PLIN2
in GNMT-KO mice resulted in a decreased turnover of TGs for
secretion in VLDL, ApoE secretion was still increased through
VLDL clearance from the blood, discarding this hypothesis.
Excess SAMe levels in the livers of GNMT-KO mice were
associated with decreased ApoB secretion. We found that the
liver content of ApoB100 was decreased as a consequence of
decreased ApoB mRNA. We also found that 3CpG islands were
hypermethylated within the ApoB promoter and that ApoBmRNA680 Journal of Hepatology 201binding to the mRNA-stabilizing HuR protein was decreased in
GNMT-KO mice, suggesting that ApoBmRNA synthesis and stabil-
ity were decreased in GNMT-KO mice.
In conclusion, all these ﬁndings show that in NAFLD increased
SAMe disrupts VLDL features and enhances VLDL clearance from
the blood stream, which may lead to an improvement in the
serum lipid proﬁle of NAFLD patients. However, the increased
lipoprotein lipid supply to tissues could also impair intracellular
lipid homeostasis and be a cause of lipid storage in muscle, heart
or adipose tissue, being involved in the extrahepatic complica-
tions of NAFLD.
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